MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/jtd-2026-0658

Медицинская библиотека · Journal of thoracic disease · 2026

Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB-IIIA non-small cell lung cancer: a propensity-weighted analysis.

Tokaz Molly, Heiden Brendan T, Eaton Daniel B, Jalal Shadia, Seyoum Nahom, Brandt Whitney S, Rossetti Nikki E, Chang Su-Hsin, Yan Yan, Puri Varun, Schoen Martin W, Thomas Theodore S

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Platinum-doublet adjuvant chemotherapy is standard of care for resected non-small cell lung cancer (NSCLC). Cisplatin has been historically favored for modest survival benefits, though its substantial toxicity often limits treatment completion in routine practice. Carboplatin is better tolerated and frequently substituted; however, comparative real-world effectiveness and safety remain unclear. We evaluated outcomes of cisplatin- versus carboplatin-based adjuvant therapy within the Veterans Health Administration (VHA).

METHODS

We conducted a retrospective cohort study of Veterans with resected stage IB-IIIA NSCLC treated with adjuvant cisplatin- or carboplatin-based doublets from 2006-2020 using national VHA data. Inverse probability of treatment weighting (IPTW) balanced demographic, clinical, and surgical characteristics. Outcomes included overall survival (OS), recurrence-free survival (RFS), renal toxicity, hospitalization, adverse event rate and treatment completion.

RESULTS

Among 465 Veterans, 242 received cisplatin and 223 carboplatin. Carboplatin recipients were older with more comorbidities. After IPTW adjustment, cisplatin was associated with higher renal toxicity (≥30% eGFR decline: 42.7% vs. 21.3%, P<0.001), greater overall adverse event burden (3.41 vs. 2.75, P=0.002), higher rates of hospitalization (46.8% vs. 35.2%, P=0.02) and lower treatment completion (37.7% vs. 55.5%, P<0.001). Five-year OS and RFS numerically favored cisplatin (61.0% vs. 48.8%, P=0.17; 63.9% vs. 56.6%, P=0.12).

CONCLUSIONS

Cisplatin-based adjuvant chemotherapy was associated with higher OS and RFS though with significantly greater toxicity, hospitalization, and lower treatment completion. These findings highlight the importance of considering the tradeoff of tolerability and treatment completion with efficacy in real-world populations to allow individualized regimen selection, particularly when cisplatin is not feasible.

Для цитирования: Tokaz Molly, Heiden Brendan T, Eaton Daniel B, Jalal Shadia, Seyoum Nahom, Brandt Whitney S, Rossetti Nikki E, Chang Su-Hsin, Yan Yan, Puri Varun, Schoen Martin W, Thomas Theodore S. Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB-IIIA non-small cell lung cancer: a propensity-weighted analysis.. Journal of thoracic disease. 2026. DOI: 10.21037/jtd-2026-0658.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.